- Home
- MYI vs CSTL Comparison
MYI vs CSTL Comparison
Compare MYI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- CSTL
- Stock Information
- Founded
- MYI 1992
- CSTL 2007
- Country
- MYI United States
- CSTL United States
- Employees
- MYI N/A
- CSTL N/A
- Industry
- MYI Investment Bankers/Brokers/Service
- CSTL Medical Specialities
- Sector
- MYI Finance
- CSTL Health Care
- Exchange
- MYI Nasdaq
- CSTL Nasdaq
- Market Cap
- MYI 736.5M
- CSTL 697.9M
- IPO Year
- MYI N/A
- CSTL 2019
- Fundamental
- Price
- MYI $11.03
- CSTL $22.75
- Analyst Decision
- MYI
- CSTL Strong Buy
- Analyst Count
- MYI 0
- CSTL 6
- Target Price
- MYI N/A
- CSTL $37.67
- AVG Volume (30 Days)
- MYI 256.7K
- CSTL 348.6K
- Earning Date
- MYI 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- MYI 4.81%
- CSTL N/A
- EPS Growth
- MYI N/A
- CSTL N/A
- EPS
- MYI N/A
- CSTL N/A
- Revenue
- MYI N/A
- CSTL $346,269,000.00
- Revenue This Year
- MYI N/A
- CSTL N/A
- Revenue Next Year
- MYI N/A
- CSTL N/A
- P/E Ratio
- MYI N/A
- CSTL N/A
- Revenue Growth
- MYI N/A
- CSTL 20.40
- 52 Week Low
- MYI $9.32
- CSTL $14.59
- 52 Week High
- MYI $11.70
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- MYI 64.97
- CSTL 52.78
- Support Level
- MYI $10.93
- CSTL $22.28
- Resistance Level
- MYI $11.10
- CSTL $23.71
- Average True Range (ATR)
- MYI 0.07
- CSTL 1.05
- MACD
- MYI -0.01
- CSTL -0.12
- Stochastic Oscillator
- MYI 63.16
- CSTL 35.90
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.